Development and Validation of a Tetra-Primer Amplification Refractory Mutation System-Polymerase Chain Reaction Combined with Melting Analysis-Assay for Clinical JAK2 V617F Mutation Detection

Molecular Diagnosis and Therapy

Volumn 18, Issue 5, 2014, Pages 579-585

  Liu, Weiwei ^a,b   Hu, Tingting ^c   Chen, Yuming ^c   Zhang, Xinju ^c   Gu, Xiaoye ^c   Guan, Ming ^c  

^a TONGJI UNIVERSITY   (China)

^b Laboratory of Shanghai Skin Diseases Hospital   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

JAK2 PROTEIN, HUMAN; JANUS KINASE 2;

GENETICS; HL 60 CELL LINE; HUMAN; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; MYELOPROLIFERATIVE DISORDERS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TRANSITION TEMPERATURE; TUMOR CELL LINE; VALIDATION STUDY;

CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; HL-60 CELLS; HUMANS; JANUS KINASE 2; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; MYELOPROLIFERATIVE DISORDERS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TRANSITION TEMPERATURE;

EID: 84933047920     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40291-014-0111-6     Document Type: Article

References (26)

1. Olsen RJ, Tang Z, Farkas DH, et al. Detection of the JAK2(V617F) mutation in myeloproliferative disorders by melting curve analysis using the LightCycler system. Arch Pathol Lab Med. 2006;130:997–1003.
2. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.
3. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–8.
4. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–90.
5. Levine RL, Loriaux M, Huntly BJ, et al. The JAK2 V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 2005;106:3377–9.
6. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005;106:1207–9.
7. Zhao ZJ, Vainchenker W, Krantz SB, et al. Role of tyrosine kinases and phosphatases in polycythemia vera. Semin Hematol. 2005;42:2212–9.
8. Wu Z, Yuan H, Zhang X, et al. Development and inter-laboratory validation of unlabeled probe melting curve analysis for detection of JAK2 V617F mutation in polycythemia vera. PLoS One. 2011;6:e26534.
9. Bracco E, Rosso V, Serra A, et al. Design and application of a novel PNA probe for the detection at single cell level of JAK2 V617F mutation in myeloproliferative neoplasms. BMC Cancer. 2013;13:348.
10. Qian J, Lin J, Yao DM, et al. Rapid detection of JAK2 V617F mutation using high-resolution melting analysis with LightScanner platform. Clin Chim Acta. 2010;411:2097–100.
11. Smith DL, Lamy A, Beaudenon-Huibregtse S, et al. A Multiplex Technology Platform for the Rapid Analysis of Clinically Actionable Genetic Alterations and Validation for BRAF p. V600E Detection in 1549 Cytologic and Histologic Specimens. Arch Pathol Lab Med. 2014;138:371–8.
12. Lay M, Mariappan R, Gotlib J, et al. Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis. J Mol Diagn. 2006;8:330–4.
13. Baris I, Etlik O, Koksal V, et al. SYBR green dye-based probe-free SNP genotyping: introduction of T-Plex real-time PCR assay. Anal Biochem. 2013;15:225–31.
14. Ye S, Dhillon S, Ke X et al. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res. 2001;29:E88-8.
15. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–97.
16. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.
17. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162.
18. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, et al. A gain-offunction mutation of JAK2 in myeloproliferative disorders. New Engl J Med. 2005;352:1779–90.
19. Sabattini E, Bacci F, Sagramoso C, et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102:83–7.
20. Atallah E, Verstovsek S. Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms. Expert Rev Anticance. 2009;9:663–70.
21. Agrawal M, Garg RJ, Cortes J, et al. Experimental therapeutics for patients with myeloproliferative neoplasias. Cancer. 2011;117:662–76.
22. Pardanani A, Vannucchi A, Passamonti F, et al. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia. 2010;25:218–25.
23. McClure R, Mai M, Lasho T. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia. 2006;20:168–71.
24. Murugesan G, Aboudola S, Szpurka H, et al. Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. Am J Clin Pathol. 2006;125:625–33.
25. Cankovic M, Whiteley L, Hawley RC, et al. Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory: evaluation of screening and quantitation methods. Am J Clin Pathol. 2009;132:713–21.
26. Olsen RJ, Tang Z, Farkas DH, et al. Detection of the JAK2V617F mutation in myeloproliferative disorders by melting curve analysis using the LightCycler system. Arch of Pathol Lab Med. 2009;130:997–1003.